Literature DB >> 34101387

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Liana Fraenkel1, Joan M Bathon2, Bryant R England3, E William St Clair4, Thurayya Arayssi5, Kristine Carandang6, Kevin D Deane7, Mark Genovese8, Kent Kwas Huston9, Gail Kerr10, Joel Kremer11, Mary C Nakamura12, Linda A Russell13, Jasvinder A Singh14, Benjamin J Smith15, Jeffrey A Sparks16, Shilpa Venkatachalam17, Michael E Weinblatt16, Mounir Al-Gibbawi18, Joshua F Baker19, Kamil E Barbour20, Jennifer L Barton21, Laura Cappelli22, Fatimah Chamseddine18, Michael George23, Sindhu R Johnson24, Lara Kahale18, Basil S Karam18, Assem M Khamis18, Iris Navarro-Millán25, Reza Mirza26, Pascale Schwab21, Namrata Singh27, Marat Turgunbaev28, Amy S Turner28, Sally Yaacoub18, Elie A Akl18.   

Abstract

OBJECTIVE: To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.
METHODS: We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
RESULTS: The guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).
CONCLUSION: This clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients' values, goals, preferences, and comorbidities.
© 2021, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34101387      PMCID: PMC9273041          DOI: 10.1002/acr.24596

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  64 in total

1.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

2.  Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.

Authors:  Michael D George; Joshua F Baker; Kevin Winthrop; Evo Alemao; Lang Chen; Sean Connolly; Jesse Y Hsu; Teresa A Simon; Qufei Wu; Fenglong Xie; Shuo Yang; Jeffrey R Curtis
Journal:  Ann Intern Med       Date:  2019-05-21       Impact factor: 25.391

Review 3.  Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies.

Authors:  Johannes W J Bijlsma; Frank Buttgereit
Journal:  Rheumatology (Oxford)       Date:  2016-12       Impact factor: 7.580

4.  How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.

Authors:  Sytske Anne Bergstra; Lai-Ling Winchow; Elizabeth Murphy; Arvind Chopra; Karen Salomon-Escoto; João Eurico Fonseca; Cornelia F Allaart; Robert B M Landewé
Journal:  Ann Rheum Dis       Date:  2018-10-16       Impact factor: 19.103

Review 5.  Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.

Authors:  Camille Roubille; Boulos Haraoui
Journal:  Semin Arthritis Rheum       Date:  2013-10-05       Impact factor: 5.532

6.  Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.

Authors:  Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

7.  Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.

Authors:  Daniel P Erhardt; Grant W Cannon; Chia-Chen Teng; Ted R Mikuls; Jeffrey R Curtis; Brian C Sauer
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-08-30       Impact factor: 4.794

8.  Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area.

Authors:  Tsai-Ling Liao; Chin-Fu Lin; Yi-Ming Chen; Hung-Jen Liu; Der-Yuan Chen
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

9.  Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.

Authors:  Louise K Mercer; Johan Askling; Pauline Raaschou; William G Dixon; Lene Dreyer; Merete Lund Hetland; Anja Strangfeld; Angela Zink; Xavier Mariette; Axel Finckh; Helena Canhao; Florenzo Iannone; Jakub Zavada; Jacques Morel; Jacques-Eric Gottenberg; Kimme L Hyrich; Joachim Listing
Journal:  Ann Rheum Dis       Date:  2016-06-15       Impact factor: 19.103

10.  Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.

Authors:  Brian C Sauer; Chia-Chen Teng; Derek Tang; Jianwei Leng; Jeffrey R Curtis; Ted R Mikuls; David J Harrison; Grant W Cannon
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

View more
  37 in total

1.  Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology.

Authors:  Saranya Panichaporn; Wanwisa Chanapai; Ananya Srisomnuek; Phakhamon Thaweeratthakul; Wanruchada Katchamart
Journal:  Patient Prefer Adherence       Date:  2022-08-17       Impact factor: 2.314

2.  High Efficacy Combined Microneedles Array with Methotrexate Nanocrystals for Effective Anti-Rheumatoid Arthritis.

Authors:  Fang Wei; Qiuyue Wang; Hang Liu; Xuejing Yang; Wenyu Cao; Weiman Zhao; Yingying Li; Lijie Zheng; Tao Ma; Qingqing Wang
Journal:  Int J Nanomedicine       Date:  2022-05-24

3.  Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? - A Cohort Study in a Colombian Population.

Authors:  Pedro Santos-Moreno; Susan Martinez; Linda Ibata; Laura Villarreal; Fernando Rodríguez-Florido; Manuel Rivero; Adriana Rojas-Villarraga; Claudio Galarza-Maldonado
Journal:  Biologics       Date:  2022-07-13

4.  A Population-Based Study Evaluating Retention in Rheumatology Care Among Patients With Rheumatoid Arthritis.

Authors:  Claire E H Barber; Diane Lacaille; Ruth Croxford; Cheryl Barnabe; Deborah A Marshall; Michal Abrahamowicz; Hui Xie; J Antonio Avina-Zubieta; John M Esdaile; Glen Hazlewood; Peter Faris; Steven Katz; Paul MacMullan; Dianne Mosher; Jessica Widdifield
Journal:  ACR Open Rheumatol       Date:  2022-05-05

5.  The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States.

Authors:  Robin K Dore; Jenya N Antonova; Chakkarin Burudpakdee; Lawrence Chang; Magdaliz Gorritz; Mark C Genovese
Journal:  ACR Open Rheumatol       Date:  2021-11-18

Review 6.  Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders.

Authors:  Kyung Rae Ko; Hyunil Lee; Soo-Hong Han; Wooyeol Ahn; Do Kyung Kim; Il-Su Kim; Bo Sung Jung; Soonchul Lee
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

Review 7.  Management of Rheumatoid Arthritis: An Overview.

Authors:  Andrei-Flavius Radu; Simona Gabriela Bungau
Journal:  Cells       Date:  2021-10-23       Impact factor: 6.600

Review 8.  miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis.

Authors:  Tomasz Kmiołek; Agnieszka Paradowska-Gorycka
Journal:  Cells       Date:  2022-01-28       Impact factor: 6.600

9.  Low-Dose Interleukin-2 Altered Gut Microbiota and Ameliorated Collagen-Induced Arthritis.

Authors:  Na Li; Xuefei Li; Rui Su; Ruihe Wu; Hong-Qing Niu; Jing Luo; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  J Inflamm Res       Date:  2022-02-25

10.  Biosimilar Uptake: The Importance of Healthcare Provider Education.

Authors:  Sonia Tadjalli Oskouei; Andrew R Kusmierczyk
Journal:  Pharmaceut Med       Date:  2021-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.